The Mataró Ageing Study Group: Ayllón J, Buquet X, Bosch A, Burdoy E, Cademas I, Dordas J, Espinosa C, Falcón I, Gordillo M, Merino MJ, Mussoll J, Palomera E, Papiol M, Pous E, Pubill M, Puig J, Puig-Domingo M (Project co-director), Sanahuja J, Serra P, Serra-Prat M (Project co-director), Serrano C, Vilardebò A, Villarroya I.
Obestatin does not modify weight and nutritional behaviour but is associated with metabolic syndrome in old women
Article first published online: 25 MAR 2013
© 2012 John Wiley & Sons Ltd
Volume 78, Issue 6, pages 882–890, June 2013
How to Cite
Mora, M., Granada, M. L., Roca, M., Palomera, E., Puig, R., Serra-Prat, M. and Puig-Domingo, M. (2013), Obestatin does not modify weight and nutritional behaviour but is associated with metabolic syndrome in old women. Clinical Endocrinology, 78: 882–890. doi: 10.1111/j.1365-2265.2012.04489.x
- Issue published online: 22 APR 2013
- Article first published online: 25 MAR 2013
- Accepted manuscript online: 9 JUL 2012 12:23AM EST
- Manuscript Accepted: 1 JUL 2012
- Manuscript Revised: 26 JUN 2012
- Manuscript Revised: 15 MAY 2012
- Manuscript Received: 26 MAR 2012
Ghrelin and obestatin have apparent opposite orexigenic and anorexigenic effects, although the latter has not been firmly demonstrated in humans. So far, little data have been reported in relation to its potential association with metabolic syndrome (MS). The objective was to study obestatin concentrations in relation to nutritional parameters and eating behaviours in old women.
Design, Patients and Measurements
Prospective study; a total of 110 women (age: 76·93 ± 6·32) from the Mataró Ageing Study were included. Individuals were characterized by anthropometric variables, lipids, glucose, blood pressure, MS components (Adult Treatment Panel III criteria), anorexia and nutritional status by Mini Nutritional Assessment Short Form (MNA-SF) and re-evaluated at 2-year follow-up. Obestatin was measured by IRMA.
58·2% of the subjects had MS; at 2-year follow-up 24·1% had a weight loss >5%, 7·2% >10%, and 26·4% changed their MNA-SF score to risk of malnutrition category. Anorexia was present in 38·4%. Obestatin levels were not related to either change of weight, MNA-SF or anorexia, but a positive correlation was found with the absolute difference between basal and 2-year waist circumference (WC) (r = 0·429; P < 0·001) and relative difference between basal and 2-year WC (r = 0·420; P < 0·001); both remained significant after adjusting for age and body mass index. When obestatin was divided into quartiles, a significant lineal trend was observed in relation to WC (P = 0·049), absolute and relative difference between basal and 2-year WC (both P < 0·001). Obestatin was associated with glucose impairment (69·0% in 4th quartile vs 47·5% in 1st to 3rd, P = 0·047; after adjustment, P = 0·098) and MS (77·8% in 4th vs 51·3% in 1st to 3rd, P = 0·017; after adjustment, P = 0·046, OR 2·90 (1·02–8·25) 4th vs 1st to 3rd).
Obestatin is elevated in aged women bearing MS but is otherwise not associated with other nutritional parameters, weight loss or anorexia.